I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| fibroblast | 7 studies | 32% ± 12% | |
| pericyte | 7 studies | 22% ± 5% | |
| adipocyte | 4 studies | 38% ± 25% | |
| connective tissue cell | 3 studies | 26% ± 8% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| fibroblast | 7 studies | 32% ± 12% | |
| pericyte | 7 studies | 22% ± 5% | |
| adipocyte | 4 studies | 38% ± 25% | |
| connective tissue cell | 3 studies | 26% ± 8% |
Insufficient scRNA-seq data for expression of TWIST1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| breast | 100% | 2275.20 | 457 / 459 | 90% | 16.30 | 1003 / 1118 |
| skin | 100% | 2666.42 | 1807 / 1809 | 89% | 31.06 | 418 / 472 |
| uterus | 97% | 1106.46 | 165 / 170 | 71% | 32.45 | 326 / 459 |
| esophagus | 91% | 459.64 | 1310 / 1445 | 75% | 12.59 | 137 / 183 |
| bladder | 100% | 726.33 | 21 / 21 | 63% | 10.02 | 315 / 504 |
| ovary | 84% | 506.11 | 151 / 180 | 74% | 14.47 | 317 / 430 |
| prostate | 60% | 214.53 | 147 / 245 | 89% | 20.96 | 447 / 502 |
| adrenal gland | 79% | 308.24 | 205 / 258 | 47% | 29.73 | 107 / 230 |
| thymus | 90% | 332.96 | 586 / 653 | 35% | 4.29 | 214 / 605 |
| stomach | 41% | 439.24 | 147 / 359 | 61% | 6.32 | 174 / 286 |
| adipose | 99% | 1338.16 | 1187 / 1204 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 93% | 13.76 | 42 / 45 |
| intestine | 35% | 105.24 | 334 / 966 | 54% | 5.64 | 287 / 527 |
| blood vessel | 85% | 580.42 | 1131 / 1335 | 0% | 0 | 0 / 0 |
| pancreas | 1% | 1.17 | 2 / 328 | 83% | 15.67 | 148 / 178 |
| lung | 6% | 19.58 | 33 / 578 | 59% | 9.25 | 684 / 1155 |
| lymph node | 0% | 0 | 0 / 0 | 48% | 3.46 | 14 / 29 |
| heart | 43% | 144.90 | 371 / 861 | 0% | 0 | 0 / 0 |
| brain | 2% | 6.03 | 63 / 2642 | 39% | 5.78 | 275 / 705 |
| kidney | 9% | 26.45 | 8 / 89 | 10% | 1.98 | 90 / 901 |
| eye | 0% | 0 | 0 / 0 | 11% | 1.54 | 9 / 80 |
| muscle | 6% | 20.84 | 49 / 803 | 0% | 0 | 0 / 0 |
| liver | 0% | 0 | 0 / 226 | 6% | 1.14 | 24 / 406 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0042473 | Biological process | outer ear morphogenesis |
| GO_0097009 | Biological process | energy homeostasis |
| GO_2000793 | Biological process | cell proliferation involved in heart valve development |
| GO_0048642 | Biological process | negative regulation of skeletal muscle tissue development |
| GO_2000679 | Biological process | positive regulation of transcription regulatory region DNA binding |
| GO_0001701 | Biological process | in utero embryonic development |
| GO_0032502 | Biological process | developmental process |
| GO_0032000 | Biological process | positive regulation of fatty acid beta-oxidation |
| GO_0045766 | Biological process | positive regulation of angiogenesis |
| GO_0003183 | Biological process | mitral valve morphogenesis |
| GO_0001649 | Biological process | osteoblast differentiation |
| GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
| GO_0010628 | Biological process | positive regulation of gene expression |
| GO_0042733 | Biological process | embryonic digit morphogenesis |
| GO_0071456 | Biological process | cellular response to hypoxia |
| GO_2000147 | Biological process | positive regulation of cell motility |
| GO_1902894 | Biological process | negative regulation of miRNA transcription |
| GO_0003180 | Biological process | aortic valve morphogenesis |
| GO_0030500 | Biological process | regulation of bone mineralization |
| GO_0001764 | Biological process | neuron migration |
| GO_0003203 | Biological process | endocardial cushion morphogenesis |
| GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
| GO_0071363 | Biological process | cellular response to growth factor stimulus |
| GO_0035115 | Biological process | embryonic forelimb morphogenesis |
| GO_0035116 | Biological process | embryonic hindlimb morphogenesis |
| GO_0060900 | Biological process | embryonic camera-type eye formation |
| GO_0051898 | Biological process | negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
| GO_0060021 | Biological process | roof of mouth development |
| GO_0050679 | Biological process | positive regulation of epithelial cell proliferation |
| GO_0035359 | Biological process | negative regulation of peroxisome proliferator activated receptor signaling pathway |
| GO_0043066 | Biological process | negative regulation of apoptotic process |
| GO_0030335 | Biological process | positive regulation of cell migration |
| GO_0060363 | Biological process | cranial suture morphogenesis |
| GO_2000144 | Biological process | positive regulation of DNA-templated transcription initiation |
| GO_0045668 | Biological process | negative regulation of osteoblast differentiation |
| GO_0001843 | Biological process | neural tube closure |
| GO_0007517 | Biological process | muscle organ development |
| GO_2000802 | Biological process | positive regulation of endocardial cushion to mesenchymal transition involved in heart valve formation |
| GO_0071639 | Biological process | positive regulation of monocyte chemotactic protein-1 production |
| GO_0045843 | Biological process | negative regulation of striated muscle tissue development |
| GO_0010718 | Biological process | positive regulation of epithelial to mesenchymal transition |
| GO_0048701 | Biological process | embryonic cranial skeleton morphogenesis |
| GO_0010936 | Biological process | negative regulation of macrophage cytokine production |
| GO_0001503 | Biological process | ossification |
| GO_0032720 | Biological process | negative regulation of tumor necrosis factor production |
| GO_0003253 | Biological process | cardiac neural crest cell migration involved in outflow tract morphogenesis |
| GO_0043518 | Biological process | negative regulation of DNA damage response, signal transduction by p53 class mediator |
| GO_2000780 | Biological process | negative regulation of double-strand break repair |
| GO_0048511 | Biological process | rhythmic process |
| GO_0032760 | Biological process | positive regulation of tumor necrosis factor production |
| GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
| GO_0061029 | Biological process | eyelid development in camera-type eye |
| GO_2000773 | Biological process | negative regulation of cellular senescence |
| GO_0032755 | Biological process | positive regulation of interleukin-6 production |
| GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0000785 | Cellular component | chromatin |
| GO_0005634 | Cellular component | nucleus |
| GO_0042803 | Molecular function | protein homodimerization activity |
| GO_0140297 | Molecular function | DNA-binding transcription factor binding |
| GO_0043425 | Molecular function | bHLH transcription factor binding |
| GO_0000977 | Molecular function | RNA polymerase II transcription regulatory region sequence-specific DNA binding |
| GO_0019904 | Molecular function | protein domain specific binding |
| GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
| GO_0000987 | Molecular function | cis-regulatory region sequence-specific DNA binding |
| GO_0001221 | Molecular function | transcription coregulator binding |
| GO_0070888 | Molecular function | E-box binding |
| GO_0001217 | Molecular function | DNA-binding transcription repressor activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0042826 | Molecular function | histone deacetylase binding |
| Gene name | TWIST1 |
| Protein name | Twist-related protein 1 Twist-related protein 1 (Class A basic helix-loop-helix protein 38) (bHLHa38) (H-twist) |
| Synonyms | TWIST BHLHA38 |
| Description | FUNCTION: Acts as a transcriptional regulator. Inhibits myogenesis by sequestrating E proteins, inhibiting trans-activation by MEF2, and inhibiting DNA-binding by MYOD1 through physical interaction. This interaction probably involves the basic domains of both proteins. Also represses expression of pro-inflammatory cytokines such as TNFA and IL1B. Regulates cranial suture patterning and fusion. Activates transcription as a heterodimer with E proteins. Regulates gene expression differentially, depending on dimer composition. Homodimers induce expression of FGFR2 and POSTN while heterodimers repress FGFR2 and POSTN expression and induce THBS1 expression. Heterodimerization is also required for osteoblast differentiation. Represses the activity of the circadian transcriptional activator: NPAS2-BMAL1 heterodimer (By similarity). . FUNCTION: Acts as a transcriptional regulator. Inhibits myogenesis by sequestrating E proteins, inhibiting trans-activation by MEF2, and inhibiting DNA-binding by MYOD1 through physical interaction. This interaction probably involves the basic domains of both proteins. Also represses expression of pro-inflammatory cytokines such as TNFA and IL1B. Regulates cranial suture patterning and fusion. Activates transcription as a heterodimer with E proteins. Regulates gene expression differentially, depending on dimer composition. Homodimers induce expression of FGFR2 and POSTN while heterodimers repress FGFR2 and POSTN expression and induce THBS1 expression. Heterodimerization is also required for osteoblast differentiation. Represses the activity of the circadian transcriptional activator: NPAS2-BMAL1 heterodimer. . FUNCTION: Acts as a transcriptional regulator. Inhibits myogenesis by sequestrating E proteins, inhibiting trans-activation by MEF2, and inhibiting DNA-binding by MYOD1 through physical interaction. This interaction probably involves the basic domains of both proteins. Also represses expression of pro-inflammatory cytokines such as TNFA and IL1B. Regulates cranial suture patterning and fusion. Activates transcription as a heterodimer with E proteins. Regulates gene expression differentially, depending on dimer composition. Homodimers induce expression of FGFR2 and POSTN while heterodimers repress FGFR2 and POSTN expression and induce THBS1 expression. Heterodimerization is also required for osteoblast differentiation. Represses the activity of the circadian transcriptional activator: NPAS2-BMAL1 heterodimer. . |
| Accessions | ENST00000443687.5 ENST00000354571.5 Q15672 H7C4D7 ENST00000242261.6 H7BY00 |
